BioMark Diagnostics Secures Key Patent in Cancer Diagnostics

BioMark Diagnostics (TSE:BUX) has released an update.

BioMark Diagnostics Inc. has received a new U.S. patent for its innovative liquid biopsy assay, enhancing its intellectual property in cancer diagnostics and promising improved management for challenging cancers like glioblastoma (GBM) and triple-negative breast cancer (TNBC). The patent solidifies BioMark’s position in the market and supports its ongoing research into effective treatment strategies, with a focus on saving lives and optimizing patient care.

For further insights into TSE:BUX stock, check out TipRanks’ Stock Analysis page.